Oral roflumilast safe and effective therapy for patients with recurrent aphthous stomatitis: Study

A study published in the International Journal of Dermatology suggests that oral roflumilast is a safe and effective therapy for patients with recurrent aphthous stomatitis.

Severe recurrent aphthous stomatitis (RAS) represents a therapeutic challenge because of its impact on the patient’s quality of life. Additionally, no approved systemic therapies are available. Roflumilast, a phosphodiesterase-4 inhibitor, has shown promise in other inflammatory dermatological conditions. This study aimed to assess the characteristics, effectiveness, and safety of roflumilast in treating RAS in routine clinical practice. This is a single cohort ambispective observational study conducted in five Spanish centers. Twenty-two patients with RAS treated with roflumilast participated. Data collection included demographic, clinical, and outcome variables. Statistical analysis compared the outcomes of 12 weeks of roflumilast treatment with a similar prior period without treatment. Results: During treatment with roflumilast, a significant reduction in flare-ups (88%) and oral ulcers (94%) was observed compared to the untreated period. A reduction in pain (66%) and ulcer duration (63%) was observed. Adverse effects (AEs) occurred in 13 patients, predominantly headache and gastrointestinal disturbances. Most of these were self-limiting or manageable with dose adjustment. Treatment was withdrawn in three cases, mainly because of AEs. This study suggests that roflumilast may effectively treat RAS by reducing the number of flare-ups and ulcers, their duration, and the symptomatology produced by the ulcers. In addition, roflumilast has a good safety profile, is well tolerated at low doses, and does not require close monitoring. These characteristics and its favorable economic profile make roflumilast a promising therapeutic option in this pathology.

Reference:

Peñuelas Leal, R., Bagan, L., Grau Echevarría, A., Peñuelas Ruiz, J.A., Zaragoza Ninet, V., Sánchez Carazo, J.L., Pérez Pastor, G., Labrandero Hoyos, C., Finello, M., Martínez Fernández, S., Blaya Imbernon, D., González García, Á., Pérez Zafrilla, E., Martí Cabrera, M. and Bagan, J. (2024), Treatment of recurrent aphthous stomatitis with oral roflumilast, a multicenter observational study. Int J Dermatol. https://doi.org/10.1111/ijd.17478

Keywords:

Oral, roflumilast, safe, effective, therapy, patient, recurrent, aphthous, stomatitis, study, International Journal of Dermatology, Peñuelas Leal, R., Bagan, L., Grau Echevarría, A., Peñuelas Ruiz, J.A., Zaragoza Ninet, V., Sánchez Carazo, J.L., Pérez Pastor, G., Labrandero Hoyos, C., Finello, M., Martínez Fernández, S., Blaya Imbernon, D., González García, Á., Pérez Zafrilla, E., Martí Cabrera

Powered by WPeMatico

Faricimab therapy closely associated with severe intraocular inflammation, reveals research

A new study published in the Journal of American Medical Association showed that rare instances of noninfectious intraocular inflammation may be linked to faricimab (Vabysmo) intravitreal injections.

The US Food and Drug Administration has approved faricimab, a humanized, biospecific immunoglobulin G (IgG) monoclonal antibody, for use as an intravitreal injection (IVI) to treat neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema caused by retinal vein occlusion. This medicinal compound is intended to improve vascular stability by inhibiting neovascularisation and hyperpermeability by targeting the vascular endothelial growth factor A (VEGF-A) and angiopoietin 2 pathways.

Clinical studies using randomization were used to prove the safety and effectiveness of drugs. Even if causality cannot be established, evidence of adverse events linked to these medications in a clinical practice context can be helpful in developing theories about less frequent safety concerns. Thereby, Mariano Cozzi and colleagues thus carried out this investigation to report and examine instances of intraocular inflammation linked to faricimab treatment in patients who were sent to a solitary European facility.

This review of an observational case series began in April 2024. The patients came from a single Swiss tertiary referral center that was academically orientated. The patients who were referred for intraocular inflammation shortly after getting an intravitreal injection of faricimab between June 1, 2022, and March 5, 2024 were included in the study. Faricimab, 6 mg was used for diabetic macular edema or neovascular age-related macular degeneration (0.05 mL of a 120 mg/mL solution). 

In this study, 12 eyes from 7 individuals over a 22-month period were found to have noninfectious intraocular inflammation following intravitreal faricimab injections. In two of these instances, anterior and posterior inflammation coexisted with retinal vasculitis. An occlusive type of artery and vein vasculitis affected one of the two eyes which resulted in nonperfusion of the macular capillaries and a clinically significant permanent decline in vision from 20/80 to 20/2000.

Moderate anterior segment inflammation without significant alterations in vision was observed in the remaining eyes. The incident of intraocular inflammation transpired following a median of 3.5 injections of faricimab. The diagnosis of inflammation was made 28 days after the previous faricimab dose. 3 individuals experienced an elevated intraocular pressure of at least 30 mm Hg. Overall, these findings highlight the significance of continuing monitoring for possibly sight-threatening intraocular inflammation following intravitreal faricimab treatment.

Reference:

Cozzi, M., Ziegler, A., Fasler, K., Muth, D. R., Blaser, F., & Zweifel, S. A. (2024). Sterile Intraocular Inflammation Associated With Faricimab. In JAMA Ophthalmology. American Medical Association (AMA). https://doi.org/10.1001/jamaophthalmol.2024.3828

Powered by WPeMatico

DMER Haryana to begin NEET PG Counselling registrations on October 18

Haryana: Through a recent notice, the DMER Haryana has notified about the commencement date for applications by NEET PG qualified candidates seeking PG medical admissions in Haryana medical colleges.

“The Director of Medical Education (DME Haryana) has informed of all the eligible candidates desirous of seeking admission to MD/MS courses in all Government/ Government Aided/ Private Unaided Medical Institutes including those under Private Universities – SGT University, Budhera, Gurugram; AI-Falah University, Village Dhoj, Faridabad and Post MBBS DNB/Post MBBS Diploma/Post Diploma DNB courses in Civil Hospitals in the State of Haryana for the Academic Session 2024-25 that the admission to various PG Courses shall be conducted through Online Combined Centralized Counselling,” the DMER Haryana stated in the notice.

The counselling schedule and Notification explaining the procedure of admission details to PG medical courses this year will be out soon.

“It is hereby notified that the Registration on the online web portal  including editing (if any) of information submitted online and submission of choices shall begin from 18/10/2024 onwards. Further, schedule of counselling -Provisional allocation of seats, schedule of Document verification, deposition of provisional tuition fee, Last date of joining etc. shall be notified later,” the DMER Haryana said.

The candidates are advised to note that the personal appearance of the candidates along with all original documents before Admission committee at Pt. Bhagwat Dayal Sharma University of Health Sciences, Rohtak is mandatory failing which his/her candidature will not be considered.

Also Read:DMER Haryana Invites Applications for MDS admissions 2024, Tentative Counselling Schedule Released

Any amendments by the State Government/Government of India, Ministry of Health & Family Welfare/MCC/NMC shall be applicable. Amendments (If any) will notified on admission web portal, the DMER Haryana notice added.

Further, the Schedule of counselling will be uploaded separately on admission portal, the notice said.

To view the official Notice, Click here :  https://medicaldialogues.in/pdf_upload/publicnoticeforscheduleofcounselingforadmissiontopgcoursessession2024-253-257044.pdf

Powered by WPeMatico

Police cannot file FIR, investigate PC PNDT Act offenses, says Allahabad HC

The Allahabad High Court recently specified that police officers are debarred from registering the FIR and investigating offenses under the Pre-conception and Pre-natal Diagnostic Techniques (Prohibition of Sex Selection) Act, 1994 (PCPNDT Act).
Only the ‘Appropriate Authority’ or the person authorized under the PC & PNDT Act can carry out the investigation and police involvement can only be sought when there is some restraint on the part of the accused persons, clarified the High Court in its recent order dated 30.09.2024.
For more information, click on the link below:

Powered by WPeMatico

No evidence for belief that nut allergens spread through aircraft ventilation systems, say experts

There is no evidence for the commonly held belief that nut allergens can be spread through aircraft ventilation systems, say allergy and aviation medicine specialists in an evidence review published in the Archives of Disease in Childhood.

Powered by WPeMatico

Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat

Around 40% of postmenopausal hormone positive breast cancer cases may be linked to excess body fat, suggests Spanish research published online in the Journal of Epidemiology & Community Health.

Powered by WPeMatico

Increase in air pollution corresponds with more patients at the hospital emergency department

Increases in levels of particulate matter in the air, even within World Health Organization guidelines, correspond with an increase in the number of patients going to the hospital emergency department, according to research presented at the European Emergency Medicine Congress.

Powered by WPeMatico

Seizures caused by children swallowing medications or illegal substances doubled over 15-year period, poison data show

New data shows that the number of children suffering a seizure after swallowing medications or illegal substances has doubled between 2009 and 2023 in the US. The findings were presented at the European Emergency Medicine Congress.

Powered by WPeMatico

Innovation at a price: The hidden costs of antibiotic development

In an age when antibiotic resistance poses a severe threat to global health, a new study sheds light on the often-overlooked hurdles of drug commercialization.

Powered by WPeMatico

Supreme Court to Decide on Stipend for FMG Internship, Notice Issued

New Delhi: The issue of non-payment of stipends to the Foreign Medical Graduates (FMGs) during their internship has been raised once again before the Apex Court as the medicos filed a plea seeking regular monthly stipends for medical graduates from abroad pursuing compulsory internships at different government medical colleges, teaching and non-teaching institutes in Kerala and Andhra Pradesh.

While considering the pleas, the Supreme Court bench on Monday issued notice to 11 Government Medical Colleges, 6 teaching and non-teaching hospitals, the Directorate of Medical Education (DME), the Directorate of Health Services, the Kerala State Medical Council, the Kerala Government, and the National Medical Commission (NMC).

This is the first case in which the non-teaching hospitals have also been made a party in the plea seeking stipends during the FMG internship. “Issue Notice”, the Apex Court bench of Justices B R Gavai and Justice Prashant Kumar Mishra ordered on 14.10.2024.

While the plea seeking stipends for the FMGs from a few medical colleges in the State of Kerala was filed through the Association of Doctors and Medical Students, the plea for the FMGs from a few colleges from the State of Andhra Pradesh was filed through the FMGs themselves, ANI has reported. The petitioners Foreign Medical Graduates were represented through advocate Tanvi Dubey.

Also Read: FMGs challenge Non-Payment of Stipend, Supreme Court Issues Notice

In the plea, the petitioners argued that non-payment of stipend clearly violates their fundamental rights. They also mentioned in the plea that if few other colleges were paying stipends to the Foreign Medical Graduates, why were they being discriminated?

Further, the petitioners have argued that there should be no discrimination between the Indian Medical Graduates and the Foreign Medical Graduates (FMGs).

Issuing notice in both the pleas, the Supreme Court tagged them with the matters concerning the payment of stipends to medical graduates from abroad, which are pending adjudication. 

Medical Dialogues had previously reported that earlier this year while considering a similar issue, the Supreme Court had observed that the FMGs cannot be treated differently and should be paid stipends during their internship like their counterparts who have done MBBS from the Indian Medical Colleges.

This observation was made by the top court bench comprising Justices Sudhanshu Dhulia and Prasanna Bhalachandra after taking note of the submissions of lawyer Tanvi Dubey, appearing for a group of doctors, that foreign medical graduates in certain medical colleges are not being paid stipends during their internships.

To view the Supreme Court order, click on the link below:

https://medicaldialogues.in/pdf_upload/fmg-internship-stipend-256970.pdf

Also Read: Supreme Court relief: FMGs to now get stipend during internship as Indian MBBS interns

Powered by WPeMatico